This article is freely available to all

ABSTRACT

Objective: Bainbridge-Ropers syndrome (BRPS) is a neurodevelopmental genetic disorder associated with mutations in the additional sex combs–like ASXL3 gene on chromosome 18q12.1. The objective of this study is to describe the comorbid psychiatric aspects of BRPS.

Methods: A retrospective review was conducted of the electronic medical records of patients diagnosed with BRPS from 2013 to 2020 at an academic medical center. Results were deidentified and presented as frequencies and percentages.

Results: Seven cases (5 White males and 2 White females) of BRPS were identified. The mean age at the time of referral was 12 years, while the mean age at diagnosis of BRPS was 7 years. Comorbid psychiatric symptoms and diagnoses associated with BRPS included global developmental delay: 6 (86%), sleep impairment: 5 (71%), autism spectrum disorder: 3 (43%), speech impairment: 2 (29%), disruptive behavior: 4 (57%), attention-deficit/hyperactivity disorder: 3 (43%), self-injurious behavior: 3 (43%), aggression: 4 (57%), and seizures: 3 (43%). All 7 patients (100%) had multiple DSM-5 diagnoses.

Conclusions: These data highlight the need for awareness of the psychiatric comorbidity of BRPS. The findings also underscore the need for further research and emphasize the importance of multidisciplinary collaboration in the prompt assessment, diagnosis, and management of patients presenting with BRPS.

Prim Care Companion CNS Disord 2021;23(3):20m02783

To cite: Ikekwere JC, Osuagwu FC, LePlatte D, et al. Comorbid psychiatric aspects of Bainbridge-Ropers syndrome. Prim Care Companion CNS Disord. 2021;23(3):20m02783.
To share: https://doi.org/10.4088/PCC.20m02783

© Copyright 2021 Physicians Postgraduate Press, Inc.

aDivision of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan
bDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois
cDepartment of Psychiatry, MidMichigan Health, Midland, Michigan
*Corresponding author: Joseph C. Ikekwere, MD, University of Michigan Health System, Rachel UpJohn Bldg, 4250 Plymouth Rd, Ann Arbor, MI 48109 ([email protected]).

 

 

Bainbridge-Ropers syndrome (BRPS) (Online Mendelian Inheritance in Man1 [OMIM] #615485) is a novel genetic condition due to alteration in the function of the additional sex combs–like ASXL3 gene on chromosome 18q12.1, which is probably caused by denovo mutation in the ASXL3 gene during egg or sperm development prior to fertilization.2 Additional sex combs–like (ASXL) proteins are mammalian homologs of addition of sex combs (ASX), a protein that regulates the balance of trithorax and polycomb function in Drosophila.2 BRPS was first described in 2013 by Bainbridge et al.2 It is characterized by severe feeding difficulties, failure to thrive, and neurologic abnormalities with significant developmental delay. Although all 4 subjects first described by Bainbridge et al2 shared similar clinical findings, these characteristics were mostly nonspecific but distinct craniofacial features such as prominent forehead, arched eyebrows, and hypertelorism. For example, the severe feeding difficulties present from birth requiring intervention occurred in 3 of 4 subjects. The subjects were a small size at birth (3 of 4), with microcephaly (3 of 4) and severe psychomotor delay, with  missed milestones (4 of 4) at their most recent evaluation. Deep palmar creases (4 of 4) and slight ulnar deviation of the hands (3 of 4) combined with a high arched palate (3 of 4) were also common.2

The ASXL3 gene has a functional role in the process of deubiquitination and is also expressed in several organ systems including the central nervous system.3 Although the function of the ASXL3 gene/protein is still a subject of continuing research, there is emerging evidence that it may modulate early brain development among other functions.3

There are approximately 30 cases documented in the scientific literature so far, while a total of 200 cases are estimated to exist worldwide, mostly in children and adolescents4 and more recently in a middle-aged adult.5 A ASXL3 support group for BRPS families currently has approximately 180 registered families with a child that has an ASXL3 variant.4 The risk of behavioral and psychiatric symptoms is increased in persons with neurodevelopmental disorders, particularly those with underlying genetic conditions.6 However, relatively little has been published on the psychiatric phenotype of BRPS. Thus far, some behavioral phenotypes mentioned, in no order of occurrence, include severe intellectual disability, nearly absent speech and language, hypotonia, and feeding difficulties as well as aggressive and autistic traits with rocking and hand flapping, periodic agitation, and sleep disturbances.2,4,5 In a minority of the patients, tonic-clonic seizure or absence seizure occur in childhood.5,710

Given the paucity of literature regarding the prevalence of comorbid psychiatric issues associated with BRPS,2,4,5,710 this article aims to add to the body of literature by describing the comorbid psychiatric aspects of BRPS.

METHODS

This study was conducted in accordance with the Declaration of Helsinki, and appropriate Institutional Review Board approval was obtained. A waiver of informed consent was deemed appropriate by our institution. We conducted a retrospective review of patients diagnosed with BRPS between 2013 and 2020 at an academic medical center. The search was conducted using the health information technology electronic medical record search engine program. The clinical notes (dictated or typed) within the electronic medical record were reviewed.

Deidentified data including demographic information such as age, ethnicity, race, sex, and age at diagnosis were captured in addition to the physical examination and psychiatric problem list. Data were deidentified and presented as frequencies and percentages.

RESULT

Seven patients with a BRPS diagnosis were identified (Table 1). All of the patients met the clinical diagnostic criteria for BRPS and 6 were confirmed with a genetic test at the time of this writing.

The mean age of the patients with BRPS at the time of referral was 12 years old, while the mean age at diagnosis was 7 years old. The age range of the patients was from 6 to 24 years. There were 5 male patients and 2 female patients with BRPS (see Table 1). Common comorbid psychiatric issues associated with BRPS included global developmental delay: 6 (86%), sleep impairment: 5 (71%), autism spectrum disorder: 3 (43%), speech impairment: 2 (29%), disruptive behavior: 4 (57%), attention-deficit/hyperactivity disorder: 3 (43%), speech delay: 2 (29%), self-injurious behavior: 3 (43%), aggression: 4 (57%), and seizure: 3 (43%). All 7 (100%) had multiple DSM-5 diagnoses. The race of the patients was non-Hispanic White: 7 (100%).

DISCUSSION

BRPS is an autosomal dominant genetic condition due to alteration in the function of the additional sex combs–like ASXL3 gene on chromosome 18q12.1.2 The function of the ASXL3 gene/protein is still a subject of discussion within the scientific community, with some data showing that it may help with modulation of early brain development among other things.3 Aside from the first 4 described cases by Bainbridge et al,2 the largest published case series4 examined 12 subjects and described the common physical signs and medical issues associated with BRPS.

Research3 has suggested that BRPS may be associated with variable physical and neurologic symptoms including seizures 3 (43%). A report by Verhoeven et al5 described the case of a 47-year-old severely intellectually disabled man who developed late-onset partially treatment-resistant tonic-clonic epilepsy in his 40s.

Furthermore, there is ample evidence showing that psychiatric disorders tend to cluster among families, suggesting a need to characterize the psychiatric manifestations of genetic anomalies.6 There is a complex interaction between genes and behavior among humans. As previously noted, the literature is sparse regarding the prevalence of comorbid psychiatric issues observed in patients with BRPS. Just like the first case described by Bainbridge et al,2 the first subject within our sample was diagnosed in 2013.

Previous studies4 reported an average age at diagnosis of 11 years old, which was similar to the mean age of 12 years old noted in our patient cohort, with an age range of 4 to 20 years. Our study had a preponderance of male cases: 5 (71%) boys versus 2 (29%) girls. This finding is at odds with a prior study4 that reported 5 (42%) male and 6 (50%) female subjects with BRPS. We are not sure what the implication of this sex difference suggests. It appears that the older patients in our sample (the oldest being aged 24 years) may have had their diagnosis missed when they were younger, since the first case documented in the literature was in 2013.

Sixty-eight percent of our patients had global developmental delay. Genetic disorders presenting in early childhood are estimated to cause approximately a quarter of cases of global developmental delay.4 Balasubramanian et al4 reported that patients with BRPS are prone to having intellectual disability and delayed walking.

Our study revealed sleep impairment in 71% of patients, which is a similar finding to that of prior research.4 Sleep problems have been documented in children with neurodevelopmental disorders.11 It has been speculated that hypotonia may contribute to sleep apnea in these children, which was confirmed in our case series by referrals for sleep study. Forty-three percent of our subjects had autism spectrum disorder diagnosis, which was also observed previously.4 Autism spectrum disorder may exhibit genetic heterogeneity by being caused by both de novo gene mutations and inheritable means.3

Twenty-nine percent of our patients had speech impairment described mostly in terms of delayed speech. In addition, 43% exhibited self-injurious behavior and 57% demonstrated aggression. Research in the autism spectrum disorder population has shown increased incidence of speech impairment, self-injurious behavior, and aggression.5

We were unable to delineate prevalence of obsessive-compulsive disorder, generalized anxiety disorder, depression, or suicidality, and little information is known about their prevalence in BRPS patients. One plausible explanation for the lack of data is that anxiety and depressive symptoms could be hard to delineate in patients with developmental delays including autism spectrum disorder, particularly those with very limited verbal skills. Nevertheless, it can be difficult to tell whether a symptom (such as repetitive questioning) is part of an anxiety disorder or the genetic syndrome itself. Thus, it is important to carefully assess changes in behavior from baseline, especially the neurovegetative symptoms (ie, disturbances in sleep, changes in appetite and energy level) and obtain as much qualitative information as possible. Also, it is possible that subjects with no speech/language impairment might better convey their depressive/anxiety feelings than a neurodevelopmentally challenged or autistic child with limited language ability.6

Another limitation of our study is the retrospective observational design in which we reviewed the problem list and charts of BRPS cases within our institution with pediatric genetic and other specialties’ referral, diagnosis, and treatment. No detailed neuropsychological battery or assessments were incorporated, as they were not completed or available on file during our review.

This study reveals that it is likely atypical for a patient with BRPS to not have comorbid psychiatric symptoms. The presence of comorbid psychiatric issues associated with BRPS should be expected when managing patients with this syndrome. It is imperative that a thorough mental health evaluation be offered promptly to patients with suspected BRPS to ensure appropriate and prompt management of any behavioral or psychiatric sequelae. Additionally, attention should be paid to sleep impairments often of the sleep apnea type, which may be related to hypotonia that is highly prevalent in patients with this syndrome.11 More studies on BRPS are needed to further elucidate the impact of these findings with regard to the management of these patients.

Submitted: August 9, 2020; accepted December 15, 2020.
Published online: June 3, 2021.
Potential conflicts of interest: None.
Funding/support: None.

Clinical Points

  • Common comorbid psychiatric issues associated with Bainbridge-Ropers syndrome include global developmental delay, sleep impairment, disruptive behavior, autism spectrum disorder, attention-deficit/hyperactivity disorder, self-injurious behavior, and aggression as well as seizure and speech impairment.
  • Given that Bainbridge-Ropers syndrome affects multiple systems, early identification and prompt referral to a multidisciplinary team including the medical geneticist is critical to reduce the morbidity associated with the condition.
  1. Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan
  2. Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois
  3. Corresponding author: Joseph C. Ikekwere, MD, University of Michigan Health System, Rachel UpJohn Bldg, 4250 Plymouth Rd, Ann Arbor, MI 48109 ([email protected]).
  4. Department of Psychiatry, MidMichigan Health, Midland, Michigan
  5. Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan
  6. Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan
  1. Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and Genetic Disorders. Updated May 8, 2021. Accessed May 10, 2021. https://www.omim.org/
  2. Bainbridge MN, Hu H, Muzny DM, et al. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med. 2013;5(2):11. PubMed CrossRef
  3. Srivastava A, Ritesh KC, Tsan YC, et al. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. Hum Mol Genet. 2016;25(3):597–608. PubMed CrossRef
  4. Balasubramanian M, Willoughby J, Fry AE, et al. Delineating the phenotypic spectrum of Bainbridge-Ropers syndrome: 12 new patients with de novo, heterozygous, loss-of-function mutations in ASXL3 and review of published literature. J Med Genet. 2017;54(8):537–543. PubMed CrossRef
  5. Verhoeven W, Egger J, Räkers E, et al. Phenotypic characterization of an older adult male with late-onset epilepsy and a novel mutation in ASXL3 shows overlap with the associated Bainbridge-Ropers syndrome. Neuropsychiatr Dis Treat. 2018;14:867–870. PubMed CrossRef
  6. Sahin M, Sur M. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science. 2015;350(6263):10.1126/science.aab3897 aab3897. PubMed CrossRef
  7. Dinwiddie DL, Soden SE, Saunders CJ, et al. De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies. BMC Med Genomics. 2013;6(1):32. PubMed CrossRef
  8. Hori I, Miya F, Ohashi K, et al. Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome. Am J Med Genet A. 2016;170(7):1863–1867. PubMed CrossRef
  9. Kuechler A, Czeschik JC, Graf E, et al. Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition. Eur J Hum Genet. 2017;25(2):183–191. PubMed CrossRef
  10. Contreras-Capetillo SN, Vilchis-Zapata ZH, Ribbón-Conde J, et al. Global developmental delay and postnatal microcephaly: Bainbridge-Ropers syndrome with a new mutation in Neurologia. 2018;33(7):484–486. PubMed CrossRef
  11. Cotton SM, Richdale AL. Sleep patterns and behaviour in typically developing children and children with autism, Down syndrome, Prader-Willi syndrome and intellectual disability. Res Autism Spectr Disord. 2010;4(3):490–500. CrossRef